Tolerability of Enteral NAC in Infants
Starting soon · Phase 1
Conditions studied: Biliary Atresia
In brief
Biliary atresia (BA) is a neonatal liver disease characterized by impaired bile flow and is the most common indication for pediatric liver transplantation. BA can be treated with the Kasai portoenterostomy (KP), a procedure that attempts to restore bile flow and slow disease progression. However, success of the KP procedure is quite variable, and lack of adjuvant medical therapies following KP is a major gap in pediatric hepatology. This study begins to explore oral N-acetylcysteine (NAC) as a potential medical therapy in BA by determining whether an oral formulation can be given to infants. The primary objective is to determine tolerability of the oral NAC formulation. The primary outcome is tolerating at least 3 out of 4 total doses without emesis. The Bayesian Optimal Interval Design (BOIN) trial design will be used to determine the maximum tolerated dose of oral NAC. Our secondary objective is to assess palatability of the oral NAC formulation by comparing facial expressions when taking oral NAC versus other medications commonly given to cholestatic infants.
Key facts
- Study ID
- NCT06260566
- Run by
- Sanjiv Harpavat
- People needed
- 12
- Starts
- 2026-10-01
- Expected to finish
- 2031-10-01
- Last updated by the study team
- 2026-03-04
Who can join
Age: 0 and older, up to 1. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- 122-273 days of life at time of enrollment
- Confirmed diagnosis of biliary atresia based on intraoperative cholangiogram
- Able to tolerate oral nutrition and medications and not on continuous tube feeds
- Anticipated inpatient admission of at least 4 days
- Legal guardian(s) consent to study enrollment after understanding the risks and investigational nature of the study
You may not qualify if…
- Gestational age of <32 weeks at birth
- Inability or contraindication to taking oral nutrition
- Neonatal intensive care unit admission
- Short bowel, or other malabsorptive, syndrome
- Decompensated liver disease (INR > 1.3 despite vitamin K administration)
- Active respiratory infection
- Severe concurrent illnesses that would interfere with the conduct and/or results of the study
- Concurrent participation in another drug trial
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.